Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection

Hepatology

Volumn 48, Issue 2, 2008, Pages 695-

  Lagging, Martin ^a   Langeland, Nina ^b   Pedersen, Court ^c   Färkkilä, Martti ^d   Buhl, Mads Rauning ^e   Mørch, Kristine ^b   Dhillon, Amar P ^f   Alsiö, Åsa ^a   Hellstrand, Kristoffer ^a   Westin, Johan ^a   Christensen, Peer ^c   Leutscher, Peter ^e   Norkrans, Gunnar ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

^e AARHUS UNIVERSITY   (Denmark)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RNA VIRUS; SHORT COURSE THERAPY; TREND STUDY;

ANTIVIRAL AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 49649118047     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22450     Document Type: Letter

References (6)

1. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. HEPATOLOGY 2004;40:1260-1265.
2. Dalgard O, Bjoro, K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. HEPATOLOGY 2008;47:35-42.
3. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
5. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. HEPATOLOGY 2008;47:1837-1845.
6. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134.